Emerging Focus on Weight-Loss Maintenance Post-GLP-1 Treatment
As GLP-1 treatments gain popularity, the food industry is pivoting towards products that support weight maintenance after discontinuation.
Discontinuation rates for GLP-1 treatments range from 36% to 65%.
Food companies are innovating to create products that assist users in maintaining weight loss.
Oral GLP-1s may encourage longer-term adherence among users.
The rising popularity of GLP-1 treatments for weight loss is prompting the food industry to explore solutions for maintaining weight after users discontinue these medications. Recent studies indicate that a significant portion of GLP-1 users, between 36% and 65%, stop their treatment within a year, leading to concerns about weight regain once they cease using the drugs. This trend has sparked interest among food manufacturers to develop supportive products aimed at helping users retain their weight loss achievements.
Historically, GLP-1 medications have been effective in reducing appetite and controlling food intake, but many users experience a return of 'food noise'—the constant preoccupation with food—once they stop taking the drugs. Caroline Young, head of insights at the Institute of Grocery Distribution, emphasizes the need for the food industry to create products that facilitate long-term weight maintenance, suggesting that brands can thrive by addressing this gap in the market.
To meet this demand, companies are already innovating. Nestlé is working on proprietary ingredient combinations designed to suppress appetite for those transitioning off GLP-1 treatments, while the Robard Corporation has introduced Biocare2, a beverage aimed at curbing appetite. These developments highlight a shift in focus from weight loss to weight maintenance, as the industry recognizes the importance of supporting users in their long-term health goals.
Despite the challenges associated with weight regain, experts believe that the GLP-1 market will continue to thrive. Michel Savini from Argon & Co. notes that while some users may discontinue treatment, many are opting to remain on GLP-1s indefinitely to avoid regaining weight. The introduction of oral GLP-1s is expected to further enhance user adherence, as these pills eliminate some of the barriers associated with injections, such as the need for needles and cold storage.
Looking ahead, the focus on weight-loss maintenance may become a significant area of innovation within the GLP-1 landscape. As food companies develop products to assist users in maintaining their weight loss, the market may see a shift towards solutions that complement the ongoing use of GLP-1 treatments. This evolving dynamic will be crucial for both consumers and the food industry as they navigate the complexities of weight management in the future.
